Antonello Mai

Pubblicazioni

Titolo Pubblicato in Anno
Biochemical functions and clinical characterizations of the sirtuins in diabetes-induced retinal pathologies INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2022
Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription NUCLEIC ACIDS RESEARCH 2022
The Nitrobenzoxadiazole Derivative NBDHEX Behaves as Plasmodium falciparum Gametocyte Selective Inhibitor with Malaria Parasite Transmission Blocking Activity PHARMACEUTICALS 2022
A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 2022
Targeting the anti-apoptotic Bcl-2 family proteins: Machine learning virtual screening and biological evaluation of new small molecules THERANOSTICS 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2022
Sirtuin modulators: past, present, and future perspectives FUTURE MEDICINAL CHEMISTRY 2022
Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors EMBO REPORTS 2022
Current HDAC Inhibitors in Clinical Trials CHIMIA 2022
Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni ACS INFECTIOUS DISEASES 2022
Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5 JOURNAL OF MEDICINAL CHEMISTRY 2022
Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5 JOURNAL OF MEDICINAL CHEMISTRY 2022
Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells CANCER GENE THERAPY 2022
Chemically Diverse S. mansoni HDAC8 Inhibitors Reduced Viability in Worm Larval and Adult Stages CHEMMEDCHEM 2022
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics MOLECULAR METABOLISM 2022
PD-L1 small-molecule modulators: a new hope in epigenetic-based multidrug cancer therapy? DRUG DISCOVERY TODAY 2022
Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells CELL DEATH & DISEASE 2022
Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells CANCER GENE THERAPY 2022
Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2022
Modulation of virulence-associated traits in Aspergillus fumigatus by BET Inhibitor JQ1 MICROORGANISMS 2022

ERC

  • PE5_18

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Synthesis of new potential bio-active compounds, particularly in the field of

  1. epigenetics: inhibitors of HDACs (unselective and class-selective), HATs, sirtuins, PRMTs, HKMTs, KDMs and DNMTs.
  2. anticancer agents.
  3. antiviral agents and anti-HIV-1 compounds belonging to the non-nucleoside reverse transcriptase inhibitor classes
  4. antibacterial, antimycobacterial and antifungal agents.
  5. CNS agents
  6. Development of new methodology for the synthesis of heterocycles. Analysis and purification of organic mixtures. Study and characterization of organic molecules.

Keywords

drug discovery
Epigenetic drugs
antiviral agents
Anticancer drugs
parasite growth inhibition

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma